ClinicalTrials.gg
Not yet recruitingNCT07443462Updated Sep 22, 2026

Evaluation of the Effects of Pulsed Electromagnetic Field on Inflammatory Knee Osteoarthritis

An interventional study of Pulsed Electromagnetic Field (PEMF) Therapy and Sham Pulsed Electromagnetic Field (PEMF) Treatments in Knee Osteoarthritis (Knee OA), sponsored by The Hong Kong Polytechnic University. Not yet recruiting. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Osteoarthritis, Knee by The Hong Kong Polytechnic University — 6 open to participants now, 6 under way, none of them phase 3. Osteoarthritis, Knee · The Hong Kong Polytechnic University.

Planned enrollment
8th of 14
50 · median 54
Started
2026
with 2 others
No phase
13 of 14
6 open now
Registered
11th of 14
by date

Among the 14 studies in Osteoarthritis, Knee by The Hong Kong Polytechnic University, this one is the 8th largest by planned enrollment, is one of 3 that started in 2026, is one of 13 with no phase, and was the 11th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

6 of the 14 studies in Osteoarthritis, Knee by The Hong Kong Polytechnic University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 55 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Osteoarthritis, Knee by The Hong Kong Polytechnic University, or all of them as a file.
02

Study summary

This study will assess the efficacy of pulsed electromagnetic field therapy in patients with inflammatory knee osteoarthritis confirmed by MRI-detected effusion-synovitis. Fifty participants will be randomly allocated into two groups. One group will receive active PEMF therapy at a specific optimized parameter twice a week for 8 weeks, while the other group will receive sham treatment using the same device without PEMF signal. The primary outcome is the change in WOMAC pain score, and secondary outcomes include knee function, stiffness, quality of life, and MRI-quantified structural changes.

Read the detailed description

Knee osteoarthritis (KOA) is a leading cause of pain and disability, posing a significant socioeconomic burden. Current treatments often focus on pain relief with safety concerns, and no disease-modifying drugs are available. Pulsed electromagnetic field (PEMF) therapy is a non-invasive and safe physical modality with potential anti-inflammatory and analgesic effects. However, existing evidence for its efficacy in KOA is inconsistent, likely because KOA is a heterogeneous disease, and previous studies have not targeted specific subtypes. The inflammatory KOA subtype, identifiable via MRI, is the most prevalent and represents a critical target for precise intervention.

Methods This study is a double-blind, randomized, placebo-controlled pilot trial. Fifty patients with inflammatory KOA, confirmed by the presence of effusion-synovitis on MRI will be recruited. Participants will be randomly assigned to receive either active PEMF therapy at a specific, optimized parameter or sham treatment twice a week for 8 weeks. The primary outcome is the change in the WOMAC pain score at 3 months after treatment. Secondary outcomes include knee function and stiffness (WOMAC), quality of life (SF-12), and quantitatively assessed structural changes on MRI (e.g., effusion synovitis volume).

Expected Results The investigators anticipate that the group receiving active PEMF therapy will show a statistically significant and clinically important greater reduction in WOMAC pain scores compared to the sham treatment group.The investigators also expect to observe improvements in secondary outcomes, including better knee function and reduced signs of inflammation on MRI in the treatment group.

Conclusion This will be the first clinical trial to evaluate PEMF therapy specifically for the inflammatory subtype of KOA. Positive findings will provide crucial evidence for a novel, non-invasive, and precise therapeutic strategy for KOA management. This has the potential to improve patient care, alleviate the disease burden, and reduce healthcare costs.

03

Conditions studied

  • Knee Osteoarthritis (Knee OA)

Keywords

  • Pulsed electromagnetic field therapy
  • Knee osteoarthritis
  • Inflammatory subtype
04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Knee visual analogue scale (VAS) pain of \<40 mm (0-100 mm)
  2. Effusion-synovitis or Hoffa synovitis MRI semi-quantitative score of ≥2 (used to determine inflammatory subtype KOA);
  3. Kellgren-Lawrence (KL) grade II and III
  4. Patients can listen, speak, read, and understand Chinese; understand the pilot study's requirements and are willing to cooperate with the investigator in conducting the pilot study
  5. Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  1. Other inflammatory arthritis (e.g., gout, reactive arthritis, rheumatoid arthritis, psoriatic arthritis, and seronegative spondyloarthropathy) and systemic lupus erythematosus.
  2. Participants with usual KOA interventions/ treatments
  3. History of knee trauma
  4. to MRI
  5. Administration of intra-articular, intramuscular, and oral within the last 4
  6. Pregnancy and lactation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    PEMF Therapy Intervention Patients with inflammatory KOA receive active PEMF therapy with optimized

    Active Pulsed Electromagnetic Field (PEMF) Therapy Active PEMF therapy at specific optimized parameters, administered twice a week for 8 weeks

    Device: Pulsed Electromagnetic Field (PEMF) Therapy

  • Placebo comparator
    : Sham PEMF Treatment Patients with inflammatory KOA receive sham PEMF treatment (no effective elect

    Sham Pulsed Electromagnetic Field (PEMF) Treatments treatment (matching device without active electromagnetic field) administered twice a week for 8 weeks

    Device: Sham Pulsed Electromagnetic Field (PEMF) Treatments

Interventions

  • DevicePulsed Electromagnetic Field (PEMF) Therapy

    Assigned Interventions

  • DeviceSham Pulsed Electromagnetic Field (PEMF) Treatments

    Matching device without active electromagnetic field) administered twice a week for 8 weeks

06

What researchers measure

Primary outcomes

  1. Feasibility outcome:adherence

    Adherence will be calculated as the actual number of completed exercise days relative to the prescribed total.

    Time frame: 3 months after treatment

Secondary outcomes

  1. Serum Levels of Inflammatory Markers and Adipokines

    The serum concentrations of the following biomarker: Interleukin-6 (picograms per milliliter, pg/mL).

    Time frame: Baseline; 3 months after treatment

  2. Western Ontario and McMaster Universities (WOMAC) pain score

    The primary outcome will be the Western Ontario and McMaster Universities (WOMAC) pain score. This scale consists of 5 questions assessing knee joint pain, each scored on a 5-point Likert scale (0 = no pain, 4 = extreme pain). The total score of the pain subscale ranges from 0 to 20, with higher scores indicating a more severe degree of pain.

    Time frame: Baseline; 3 months after treatment

  3. Measurement of biomarkers on MRI images of the knee

    Cartilage defects (grades 0-4). A higher score indicates more severe pathology.

    Time frame: Baseline; 3 months after treatment

  4. Ultrousound measurement

    The severity of the following pathologies will be assessed via ultrasonography using semi-quantitative scoring systems: Synovitis(0-3), Osteophytes(0-3), Cartilage damage(0-3). A higher score indicates more severe pathology.

    Time frame: Baseline, 1and 3 months after treatment

  5. Six-Minute Walk Distance

    The total distance walked during the Six-Minute Walk Test, measured in meters (m).

    Time frame: Baseline;3 months after treatment

  6. 30-Second Chair Stand Test Repetitions

    The maximum number of repetitions of rising fully from a standard-height chair without using arms, sitting back down, and fully rising again, completed within 30 seconds.

    Time frame: Baseline; 3 months after treatment]

  7. Timed Up and Go Test Time

    The time required to complete the Timed Up and Go Test (rising from a chair, walking 3 meters, turning around, walking back, and sitting down), measured in seconds (s).

    Time frame: Baseline; 3 months after treatment

  8. 12-Item Short Form Health Survey Score

    Assesses overall health-related quality of life. This scale comprises 12 items, which are aggregated into summary scores for physical and mental health. The scores are transformed to a range of 0 to 100, with higher scores indicating better health status.

    Time frame: Baseline; 3 months after treatment

  9. Patient Health Questionnaire-9 (PHQ-9) Score

    Assesses the severity of depressive symptoms. This scale consists of 9 items, each scored from 0 to 3. The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms.

    Time frame: Baseline; 3 months after treatment

  10. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score

    Assesses the severity of knee stiffness. This subscale contains 2 items, each rated on a 5-point Likert scale (0 = none, 4 = extreme). The total subscale score ranges from 0 to 8, with higher scores indicating worse stiffness.

    Time frame: Baseline; 3 months after treatment

  11. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score

    Assesses knee-related difficulty in performing daily activities. This subscale contains 17 items, each rated on a 5-point Likert scale (0 = none, 4 = extreme). The total subscale score ranges from 0 to 68, with higher scores indicating worse physical function.

    Time frame: Baseline; 3 months after treatment

  12. Serum Levels of Interleukin-6

    The serum concentrations of the following biomarkers will be measured: Interleukin-6 (picograms per milliliter, pg/mL)

    Time frame: Baseline; 3 months after treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2028, 27 months later.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 27 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Mar 2, 2026
StartEst.
Sep 15, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07443462
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 22, 2026

Study contacts

Ye LI
Contact
ye-julie.li@polyu.edu.hk
+85227664842

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion